The goal of the CAN-SAD Study is to help us understand the effect that cannabidiol (CBD) may have on physical, mental, and brain imaging measures in adults who have been diagnosed with social anxiety disorder (SAD). This study is conducted by researchers at the Massachusetts Institute of Technology (MIT) and Massachusetts General Hospital (MGH).
This will be one of the first neuroimaging studies to examine the effects of cannabidiol (CBD) in the brains of individuals with social anxiety disorder. Specifically, we will examine how a socially stressful situation impacts several different measures of stress in those diagnosed with social anxiety disorder (SAD), determine if CBD is useful in reducing symptoms of anxiety, and relate these findings with brain imaging. We hope that this research will further our understanding of the effects of CBD and inform its potential use for the treatment of SAD.
Participation in the main study is possible only if you have been selected through an initial screening phase to become a participant in the research. The screening phase will include an online pre-screening questionnaire and a telephone clinical interview.
Participation: To participate, you must be between 18-55 years old, and be able to have an MRI scan. You must also not be currently consuming any illicit substances and be willing to consume CBD.
Compensation
You will be compensated up to $260, receive a picture of your brain and contribute to scientific knowledge!
Contact us
Please contact us through email using the buttons below.
